Jesse Wayne Hall - May 1, 2025 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Chief Medical Officer
Signature
/s/ Matthew Rothman, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
May 1, 2025
Transactions value $
$0
Form type
4
Date filed
5/5/2025, 04:32 PM
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hall Jesse Wayne Chief Medical Officer C/O ACLARIS THERAPEUTICS, INC., 701 LEE ROAD, SUITE 103, WAYNE /s/ Matthew Rothman, Attorney-in-Fact 2025-05-05 0002065269

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Award $0 +146K $0.00 146K May 1, 2025 Common Stock 146K Direct F1, F2
transaction ACRS Employee Stock Option (right to buy) Award $0 +510K $0.00 510K May 1, 2025 Common Stock 510K $1.38 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2 The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of May 1, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F3 Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of May 1, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.